Company-wide revenue
Reported revenue in 2021 ¥703.3B Reported revenue in 2025 ¥1.13T
- growth amount
- +¥428.57B
- growth annualized
- +12.6%
- growth total
- +60.9%
Japanese company profile · 4543
Official English company name published by the issuer.
Original Japanese company name: テルモ株式会社
Name follows the issuer's official English company information. English company name source
FY2025 · fiscal year ended March 2026Latest filing date: 2026-06-23What does this company do?
In its FY2025 public filing, Terumo Corporation reports Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, Terumo Organ Technologies. The page shows business-level revenue and profit where the source disclosures support comparison.
Terumo Corporation's largest reported business by revenue in FY2025 was Cardiac and Vascular Company.
The business with the highest reported segment profit in FY2025 was Cardiac and Vascular Company.
FY2025 · fiscal year ended March 2026 · View original filing ↗ The source document may be in Japanese.
IFRS · Consolidated company-wide
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
Cardiac and Vascular Company
| Business | Revenue from external customers | Share of company sales | Segment profit (loss) | Margin |
|---|---|---|---|---|
| Cardiac and Vascular Company | ¥676.42B ↗ | — | ¥163.99B ↗ | 24.2% |
| Blood and Cell Technologies Company | ¥231.04B ↗ | — | ¥33.63B ↗ | 14.6% |
| Medical Care Solutions Company | ¥216.14B ↗ | — | ¥21.57B ↗ | 10.0% |
| Terumo Organ Technologies | ¥7.99B ↗ | — | ¥1.67B ↗ | 20.9% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
Reported Revenue from external customers by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cardiac and Vascular Company | ¥397.13B | ¥480.61B | ¥555.72B | ¥624.36B | ¥676.42B |
| Medical Care Solutions Company | ¥185.34B | ¥191.75B | ¥197.57B | ¥211.24B | ¥216.14B |
| Blood and Cell Technologies Company | ¥120.59B | ¥147.6B | ¥168.33B | ¥200.28B | ¥231.04B |
| Terumo Organ Technologies | — | — | — | — | ¥7.99B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
Reported revenue in 2021 ¥703.3B Reported revenue in 2025 ¥1.13T
This describes a reported period; it is not a forecast.
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
Source
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YGMG
View original filing ↗